Interaction study between antiplatelet agents, anticoagulants, thyroid replacement therapy and a bioavailable formulation of curcumin (Meriva®).

Abstract

OBJECTIVE:

The objective of this clinical study is to evaluate possible interactions between antiplatelet agents, anticoagulants, thyroid hormone replacement therapy and a formulation of curcumin (Meriva®) that resulted effective for the complementary treatment of osteoarthritis.

PATIENTS AND METHODS:

Interaction between antiplatelet agents and Meriva® was evaluated by measuring anti-platelet activity with the in-vivo bleeding-time (BT) in patients assuming acetylsalicylic acid or ticlopidine or clopidogrel from at least 2 years. The BT was evaluated before and after 10 days of supplementation with Meriva®. The interaction between anticoagulants and Meriva® was evaluated in patients using warfarin or dabigatran for previous venous thrombosis. The INR level was evaluated before and after 10 days of supplementation with the curcumin formulation. Thyroid function tests in hypothyroid patients using LT4 replacement therapy (Eutirox®) were evaluated before and after 15 days of supplementation with Meriva®. Similarly, levels of glycemia and glycated hemoglobin were evaluated in diabetic patients in treatment with metformin, before and after 10 days of supplementation with the studied product.

RESULTS:

After 10 days of supplementation with Meriva® the average BT value was not significantly different for patients assuming acetylsalicylic acid, ticlopidine or clopidogrel at standard dosages. Similarly, after 10 days of Meriva® treatment, the INR level in the two groups of patients assuming warfarin or dabigatran was not statistically different from that observed at baseline. In the analyzed patients assuming LT4 or metformin, no interactions between the therapy and Meriva® were observed.

CONCLUSIONS:

Results from this non-interaction clinical study suggest that Meriva® does not interfere with the antiplatelet activity of the most common antiplatelet agents nor alters the INR values in stable patients assuming warfarin or dabigatran. Similarly, dosages of LT4 or metformin do not need to be adjusted in case of complementary treatment with Meriva®.

• Authors: S Hu, G Belcaro, M Dugall, P Peterzan, M Hosoi, A Ledda, A Riva, L Giacomelli, S Togni, R Eggenhoffner, R Cotellese
• Journal: European review for medical and pharmacological sciences (Eur Rev Med Pharmacol Sci) Vol. 22 Issue 15 Pg. 5042-5046 (08 2018) ISSN: 2284-0729 [Electronic] Italy
• PMID: 30070343 (Publication Type: Journal Article)

Chemical References

• Anticoagulants
• Blood Glucose
• Glycated Hemoglobin A
• Platelet Aggregation Inhibitors
• Warfarin
• Clopidogrel
• Curcumin
• Ticlopidine
• Thyroxine
• Aspirin

Topics

• Anticoagulants (chemistry, therapeutic use)
• Aspirin (chemistry, therapeutic use)
• Blood Glucose (analysis)
• Clopidogrel (chemistry, therapeutic use)
• Curcumin (chemistry, therapeutic use)
• Drug Compounding
• Drug Interactions
• Female
• Glycated Hemoglobin (analysis)
• Humans
• Male
• Middle Aged
• Osteoarthritis (drug therapy, pathology)
• Platelet Aggregation Inhibitors (chemistry, therapeutic use)
• Thyroxine (chemistry, therapeutic use)
• Ticlopidine (chemistry, therapeutic use)
• Warfarin (chemistry, therapeutic use)